PROBLEM TO BE SOLVED: To provide an oral dosage form containing a medicine having unpleasant taste with which unpleasant taste in oral cavity is reduced and which has an excellent leaching property. SOLUTION: A glycerol fatty acid ester (e.g. glycerol monofatty acid ester) an acrylic acid copolymer and a plasticizer (e.g. triethyl citrate) are heated and melted to coat on the surface of a multi-core type micro capsule containing a medicine having unpleasant taste (e.g. famotidine) as a core mat...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments the ibuprofen is in direct physical contact with the famotidine.

Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments the ibuprofen is in direct physical contact with the famotidine.

The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition which is intended for the treatment of pathologies linked to gastric hyperacidity comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine ranitidine famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of and lesions caused by gastroesophageal refl...

L'invention concerne une nouvelle association pharmaceutique. La composition pharmaceutique pour le traitement des pathologies liées à l'hyperacidité gastrique comporte en combinaison le ténatoprazole et un ou plusieurs antagonistes des récepteurs H2 à l'histamine choisis parmi la cimétidine la ranitidine la famotidine et la nizatidine. Application notamment au traitement des ulcères gastriques et duodénaux et des symptômes et lésions du reflux gastro-oesophagien.

The present invention provides to methods and compositions that treat or prevent deleterious effects associated with alcohol consumption including alcohol-induced flush reaction and hangover. The methods and compositions include famotidine and optionally succinic acid. The present invention further demonstrates compositions that include famotidine are effective at treating symptoms associated with a flush reaction in subjects that are not significantly responsive to treatments with the H1 antago...